-
All Resources
(choose a category)
-
All Resources
-
Evidence
Evidence, advice, guidance and standards
-
Improvement
Improvement and implementation support
-
Scrutiny
Assurance, scrutiny, measurement and reporting
-
-
Healthcare Area
- Blood and immune system
- Cancer
- Cardiovascular system
- Caring for older people
- Dermatology
- Digestive system
- Ear, nose and throat
- Endocrine, nutritional and metabolic
- Eye
- Genitourinary system
- Health service organisation and delivery
- Infectious disease
- Mental and behavioural disorders
- Musculoskeletal system
- Nervous system
- Obstetrics and gynaecology
- Paediatrics
- Public health
- Respiratory system
- Resource Type
- Programme
- Year
- prev
- Page 6 of 1
7 results found filtered by 2010 Remove 2010 Filter 2011 Remove 2011 Filter Musculoskeletal system Remove Musculoskeletal system Filter Clear Search
-
Appraisal Guidance No. 204 Denosumab for the prevention of osteoporotic fractures
- Published
- 27 October 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 195 – Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid
- Published
- 25 August 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 199 – Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
- Published
- 25 August 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 198 – Tocilizumab for the treatment of rheumatoid arthritis
- Published
- 25 August 2010
- Cycle of Improvement
- Evidence
-
Evidence based assessment report 2010-002
- Published
- 29 April 2010
- Cycle of Improvement
- Evidence
-
Appraisal Guidance No 186 – Certolizumab pegol for the treatment of rheumatoid arthritis
- Published
- 24 February 2010
- Cycle of Improvement
- Evidence
-
Evidence based assessment report 2010-001
- Published
- 23 February 2010
- Cycle of Improvement
- Evidence